Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines

Makoto Kubo, Masayo Umebayashi, Kanako Kurata, Hitomi Mori, Masaya Kai, Hideya Ohnishi, Mitsuo Katano, Masafumi Nakamura, Takashi Morisaki

研究成果: ジャーナルへの寄稿記事

抄録

Background/Aim: Epithelial cell adhesion molecule (EpCAM) is expressed in various types of cancer, including breast cancer, and is correlated with metastasis, invasion, therapeutic resistance and prognosis. Moreover, several cell surface markers, such as CD44 and EpCAM, are molecular targets on cancer stem-like cells of breast cancer. The aim of this study was to investigate whether catumaxomab, a clinical-grade bispecific antibody that binds to both EpCAM on tumor cells and CD3 on T-cells, combined with activated T-cells can eliminate chemoresistant triple-negative breast cancer (TNBC) cells in vitro. Materials and Methods: First, a cell line (MUK-BC1) was established from human breast carcinoma cells derived from a patient with chemoresistant and disseminated breast cancer. These EpCAM-positive TNBC cells were almost completely resistant to various drug-mediated cytotoxicities up to a concentration of 10 μg/ml. Results: Pre-treatment with catumaxomab and subsequent addition of interleukin-2/OKT3-activated autologous T-cells eliminated EpCAM-positive TNBC cells. Conclusion: Catumaxomab combined with activated T-cells may be a potent therapeutic modality to overcome chemoresistant EpCAM-positive TNBC cells.

元の言語英語
ページ(範囲)4273-4279
ページ数7
ジャーナルAnticancer Research
38
発行部数7
DOI
出版物ステータス出版済み - 7 1 2018

Fingerprint

Triple Negative Breast Neoplasms
T-Lymphocytes
Cell Line
Breast Neoplasms
Bispecific Antibodies
Muromonab-CD3
Neoplastic Stem Cells
catumaxomab
Epithelial Cell Adhesion Molecule
Interleukin-2
Therapeutics
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines. / Kubo, Makoto; Umebayashi, Masayo; Kurata, Kanako; Mori, Hitomi; Kai, Masaya; Ohnishi, Hideya; Katano, Mitsuo; Nakamura, Masafumi; Morisaki, Takashi.

:: Anticancer Research, 巻 38, 番号 7, 01.07.2018, p. 4273-4279.

研究成果: ジャーナルへの寄稿記事

Kubo, Makoto ; Umebayashi, Masayo ; Kurata, Kanako ; Mori, Hitomi ; Kai, Masaya ; Ohnishi, Hideya ; Katano, Mitsuo ; Nakamura, Masafumi ; Morisaki, Takashi. / Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines. :: Anticancer Research. 2018 ; 巻 38, 番号 7. pp. 4273-4279.
@article{640c8ce533f94c28902103f5d368b322,
title = "Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines",
abstract = "Background/Aim: Epithelial cell adhesion molecule (EpCAM) is expressed in various types of cancer, including breast cancer, and is correlated with metastasis, invasion, therapeutic resistance and prognosis. Moreover, several cell surface markers, such as CD44 and EpCAM, are molecular targets on cancer stem-like cells of breast cancer. The aim of this study was to investigate whether catumaxomab, a clinical-grade bispecific antibody that binds to both EpCAM on tumor cells and CD3 on T-cells, combined with activated T-cells can eliminate chemoresistant triple-negative breast cancer (TNBC) cells in vitro. Materials and Methods: First, a cell line (MUK-BC1) was established from human breast carcinoma cells derived from a patient with chemoresistant and disseminated breast cancer. These EpCAM-positive TNBC cells were almost completely resistant to various drug-mediated cytotoxicities up to a concentration of 10 μg/ml. Results: Pre-treatment with catumaxomab and subsequent addition of interleukin-2/OKT3-activated autologous T-cells eliminated EpCAM-positive TNBC cells. Conclusion: Catumaxomab combined with activated T-cells may be a potent therapeutic modality to overcome chemoresistant EpCAM-positive TNBC cells.",
author = "Makoto Kubo and Masayo Umebayashi and Kanako Kurata and Hitomi Mori and Masaya Kai and Hideya Ohnishi and Mitsuo Katano and Masafumi Nakamura and Takashi Morisaki",
year = "2018",
month = "7",
day = "1",
doi = "10.21873/anticanres.12724",
language = "English",
volume = "38",
pages = "4273--4279",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Catumaxomab with activated T-cells efficiently lyses chemoresistant EpCAM-positive triple-negative breast cancer cell lines

AU - Kubo, Makoto

AU - Umebayashi, Masayo

AU - Kurata, Kanako

AU - Mori, Hitomi

AU - Kai, Masaya

AU - Ohnishi, Hideya

AU - Katano, Mitsuo

AU - Nakamura, Masafumi

AU - Morisaki, Takashi

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background/Aim: Epithelial cell adhesion molecule (EpCAM) is expressed in various types of cancer, including breast cancer, and is correlated with metastasis, invasion, therapeutic resistance and prognosis. Moreover, several cell surface markers, such as CD44 and EpCAM, are molecular targets on cancer stem-like cells of breast cancer. The aim of this study was to investigate whether catumaxomab, a clinical-grade bispecific antibody that binds to both EpCAM on tumor cells and CD3 on T-cells, combined with activated T-cells can eliminate chemoresistant triple-negative breast cancer (TNBC) cells in vitro. Materials and Methods: First, a cell line (MUK-BC1) was established from human breast carcinoma cells derived from a patient with chemoresistant and disseminated breast cancer. These EpCAM-positive TNBC cells were almost completely resistant to various drug-mediated cytotoxicities up to a concentration of 10 μg/ml. Results: Pre-treatment with catumaxomab and subsequent addition of interleukin-2/OKT3-activated autologous T-cells eliminated EpCAM-positive TNBC cells. Conclusion: Catumaxomab combined with activated T-cells may be a potent therapeutic modality to overcome chemoresistant EpCAM-positive TNBC cells.

AB - Background/Aim: Epithelial cell adhesion molecule (EpCAM) is expressed in various types of cancer, including breast cancer, and is correlated with metastasis, invasion, therapeutic resistance and prognosis. Moreover, several cell surface markers, such as CD44 and EpCAM, are molecular targets on cancer stem-like cells of breast cancer. The aim of this study was to investigate whether catumaxomab, a clinical-grade bispecific antibody that binds to both EpCAM on tumor cells and CD3 on T-cells, combined with activated T-cells can eliminate chemoresistant triple-negative breast cancer (TNBC) cells in vitro. Materials and Methods: First, a cell line (MUK-BC1) was established from human breast carcinoma cells derived from a patient with chemoresistant and disseminated breast cancer. These EpCAM-positive TNBC cells were almost completely resistant to various drug-mediated cytotoxicities up to a concentration of 10 μg/ml. Results: Pre-treatment with catumaxomab and subsequent addition of interleukin-2/OKT3-activated autologous T-cells eliminated EpCAM-positive TNBC cells. Conclusion: Catumaxomab combined with activated T-cells may be a potent therapeutic modality to overcome chemoresistant EpCAM-positive TNBC cells.

UR - http://www.scopus.com/inward/record.url?scp=85049785579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049785579&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12724

DO - 10.21873/anticanres.12724

M3 - Article

VL - 38

SP - 4273

EP - 4279

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -